Zardaverine

Zardaverine is a dual-selective PDE3/4 phosphodiesterase inhibitor.[1] Studies in vitro suggest that it may have useful anti-cancer properties.[2]

Zardaverine
Names
Preferred IUPAC name
6-[3-(Difluoromethoxy)-4-methoxyphenyl]pyridazin-3(2H)-one
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C12H10F2N2O3/c1-18-10-6-7(2-4-9(10)19-12(13)14)8-3-5-11(17)16-15-8/h2-6,12H,1H3,(H,16,17)
    Key: HJMQDJPMQIHLPB-UHFFFAOYSA-N
  • COC1=C(C=CC(=C1)C2=NNC(=O)C=C2)OC(F)F
Properties
C12H10F2N2O3
Molar mass 268.220 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

References
  1. Kümmerle, AE; Schmitt, M; Cardozo, SV; Lugnier, C; Villa, P; Lopes, AB; Romeiro, NC; Justiniano, H; Martins, MA; Fraga, CA; Bourguignon, JJ; Barreiro, EJ (2012). "Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors". Journal of Medicinal Chemistry. 55 (17): 7525–45. doi:10.1021/jm300514y. PMID 22891752.
  2. Corsello SM, Nagari RT, Spangler RD, et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nature Cancer (2020). doi:10.1038/s43018-019-0018-6
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.